Venaxis to Present at September Investor Conferences

CASTLE ROCK, Colo., Aug. 28, 2014 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in the emergency room who are at low risk for appendicitis, today announced it will present at three upcoming investor conferences: the Rodman & Renshaw 16^th Annual Global Investment Conference being held in New York on September 8-10, 2014, the Aegis Capital 2014 Healthcare & Technology Conference being held in Las Vegas on September 10-13, 2014, and the 5^th Annual Craig-Hallum Alpha Select Conference being held in New York on September 18, 2014.

Steve Lundy, President and CEO of Venaxis, will provide an overview of the Company's business at each of the conferences and will be available for one-on-one meetings with investors who attend.

Event:  Rodman & Renshaw 16^th Annual Global Investment Conference
Presentation:  Tuesday, September 9, 2014, 10:00 am (Eastern Time)
Location:  New York Palace Hotel; New York, NY

A live webcast of the Rodman & Renshaw presentation will be available through the investor relations section of the Venaxis website at ir.venaxis.com. The webcast replay will remain available for 90 days following the live presentation.

Event:  Aegis Capital 2014 Healthcare & Technology Conference
Presentation:  Friday, September 12, 2014, 1:00 pm (Pacific Time)
Location:  Encore at Wynn; Las Vegas, NV     

Event:  5^th Annual Craig-Hallum Alpha Select Conference
Presentation:  Thursday, September 18, 2014, 3:30 pm (Eastern Time)
Location:  Convene Conference Center; New York, NY

About Venaxis, Inc. 
Venaxis, Inc. is an in vitro diagnostic company focused on the clinical development and commercialization of its CE Marked APPY1 Test, the Company's rapid blood based test for appendicitis. This unique appendicitis test has projected high sensitivity and negative predictive value and is being developed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management. The APPY1 Test is being developed initially for pediatric, adolescent, and young adult patients with abdominal pain, as this population is at the highest risk for appendicitis and has the highest risk of long-term health effects associated with CT imaging. While FDA clearance is being sought, a limited commercial launch for the APPY1 Test is ongoing in select European countries. For more information, visit www.venaxis.com.

Forward-Looking Statements
This press release includes "forward-looking statements" of Venaxis, Inc. ("Venaxis") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that Venaxis believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors Venaxis believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Venaxis. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to obtain FDA clearance or approval, maintain CE Marking, cost effectively manufacture and generate revenues from the APPY1 Test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-K for the year ended December 31, 2013, filed with the SEC on March 28, 2014.

Venaxis is a registered trademark and APPY1 is a trademark of Venaxis, Inc.

Contact – Jed Mahan, [email protected]; (303) 794-2000 Ext. 255

SOURCE Venaxis, Inc.